Neurogene Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
Business Address 535 W 24TH STREET, NEW YORK, NY, 10011
Mailing Address 535 W 24TH STREET, NEW YORK, NY, 10011
Phone (877) 237-5020
Fiscal Year End 1231
EIN 980542593
Financial Overview
FY2025
$25.36M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 30, 2026 | View on SEC |
| 4 Insider stock transaction report | March 30, 2026 | View on SEC |
| 4 Insider stock transaction report | March 30, 2026 | View on SEC |
| 10-K Annual financial report | March 24, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
Annual Reports
10-K March 24, 2026
- Advancement of NGN-401 clinical trials with positive early tolerability data.
- Proprietary EXACT technology platform designed to prevent gene therapy toxicity.
Insider Trading
SELL 4 insiders
10 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.